Lexology September 4, 2024
It’s been a busy month for life sciences M&A, with a notable focus on smaller deals over blockbusters. Key themes throughout August include:
- exciting developments in the space of AIDD
- drugs addressing big patient populations remain in vogue
- another medtech acquisition for JNJ.
Our life sciences M&A deal of the month goes to Recursion and Exscentia in their announced combination creating a global techbio powerhouse focused on technology-enabled drug discovery. This transatlantic merger brings together $850m in balance sheet value, over US$100m in synergies and a complementary pipeline with approximately ten clinical readouts expected over the next 18 months. The merger follows a period of challenge within the industry as to whether the benefits of AI in the...
Today's Sponsors
Today's Sponsor